A Rapid Immunization Strategy with a Live-Attenuated Tetravalent Dengue Vaccine Elicits Protective Neutralizing Antibody Responses in Non-Human Primates

Dengue viruses (DENVs) cause approximately 390 million cases of DENV infections annually and over 3 billion people worldwide are at risk of infection. No dengue vaccine is currently available nor is there an antiviral therapy for DENV infections. We have developed a tetravalent live-attenuated DENV...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Ambuel, Yuping, Young, Ginger, Brewoo, Joseph N., Paykel, Joanna, Weisgrau, Kim L., Rakasz, Eva G., Haller, Aurelia A., Royals, Michael, Huang, Claire Y.-H., Capuano, Saverio, Stinchcomb, Dan T., Partidos, Charalambos D., Osorio, Jorge E.
Format: Artigo
Langue:Inglês
Publié: Frontiers Media S.A. 2014
Sujets:
Immunology
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4046319/
https://ncbi.nlm.nih.gov/pubmed/24926294
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2014.00263
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires